Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT
Sagimet Biosciences Inc. - Series A — Sagimet Biosciences — Corporate Update (August 2026)
22 slides from Sagimet Biosciences Inc. - Series A's corporate update, Aug 11, 2026
Slide 1: Targeting Metabolic Dysfunction with Novel Therapeutics
Targeting Metabolic Dysfunction with Novel Therapeutics August 2026 Exhibit 99.2
Slide 2: Forward-Looking Statements and Disclaimer
Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of histori
Slide 3: Leadership Team with Proven Development and Commercialization Experience
Dave Happel President & CEO >20 years of experience in executive leadership in biotech and pharma Brought multiple innovative healthcare products to the market Andreas Grauer Chief Medical Officer > 20 years of experience in Clinical Development and Medical Affairs across a broad range of therapeuti
Slide 4: Sagimet at a Glance: Differentiated Dermatology Assets with Clinical Validation
TVB-3567 in Acne Unique MOA: FASN Inhibition Sagimet at a Glance: Differentiated Dermatology Assets with Clinical Validation Our lead molecule, denifanstat, is a novel fatty acid synthase (FASN) inhibitor with a differentiated method of action with the potential to target multiple underserved diseas
Slide 5: Denifanstat in Other Indications; Strong IP, Cash Position, and Collaboration Potential
Denifanstat in Other Indications Strong IP, Cash Position, and Collaboration Potential Successful outcome of Phase 2b clinical trial in MASH (metabolic dysfunction-associated steatohepatitis); met both primary endpoints with significant reduction in fibrosis Pre-clinical data demonstrated synergisti
Slide 6: Development Pipeline: Multiple Indications and Clinical Milestones
Therapeutic Area Indication Stage of Development Milestone / Program Updates Preclinical Phase 1 Phase 2 Phase 3 Dermatology Acne Phase 3 clinical trial for the US expected to initiate in 2H 2026 Phase 1 FIH clinical trial initiated in June 2025 Topical formulation in development Met all primary and
Slide 7: FASN Inhibition Offers Differentiated MOA in Acne
FASN Inhibition Offers Differentiated MOA in Acne
Slide 8: Potential Role of FASN Inhibitors in the Pathogenesis of Acne
4 key drivers of acne1: Increased sebum in sebaceous glands (80% of lipids produced through DNL)2 Abnormal or excessive follicular hyper-keratinization Accelerated bacterial growth (C. acnes) Localized inflammatory response Potential Role of FASN Inhibitors in the Pathogenesis of Acne 1. Vasam M, et
Slide 9: Acne Market Overview
Blackheads Whiteheads Papules & Pustules Cysts & Nodules Acne Market Overview Global acne market is expected to reach $20B by 20341 50 million people suffer with acne in the US annually2 Acne is one of the most common skin conditions in the United States, with approximately 50 million Americans affe
Slide 10: Acne Treatment Algorithm
Moderate to Severe Disease Mild Disease Acne Treatment Algorithm Disease management involves flare and prevention intervention Treatment includes topical agents used as mono or combination therapy Main topical therapies: Retinoids Benzoyl Peroxide Antibiotics Clascoterone Salicylic Acid Azelaic Acid
Slide 11: Denifanstat's Clinical Data in Acne
Denifanstat’s Clinical Data in Acne
Slide 12: Pharmacodynamic Data Support Mechanism of Action of Denifanstat in Acne
Pharmacodynamic Data Support Mechanism of Action of Denifanstat in Acne Demonstrated a >90% reduction in sebum lipids by day 151,2 Maintained the reduced level of sebum lipids through the entire study1,2 Demonstrated a dose responsive impact on sebum lipids1,2 Note: denifanstat dose in this Phase 1
Slide 13: Ascletis Acne Phase 3 Clinical Trial Design
Ascletis Acne Phase 3 Clinical Trial Design Moderate to severe acne Multi-center placebo controlled 1:1 randomization Double-blind Once daily oral dosing 480 patients in China Co-primary endpoints at week 12 % patients who achieve IGA success (defined as at least a 2-point reduction in IGA from base
Slide 14: Ascletis Acne Phase 3 Clinical Trial Met All Primary and Secondary Endpoints
Ascletis Acne Phase 3 Clinical Trial Met All Primary and Secondary Endpoints Baseline Characteristics 50mg denifanstat (n=240) Placebo (n=240) Total lesion count 102.2 102.1 Inflammatory lesion count 42.1 43.1 IGA=3 (moderate), % 85.8 85.8 IGA=4 (severe), % 14.2 14.2 Efficacy endpoints 1 50mg denifa
Slide 15: Ascletis Acne Phase 3 Clinical Trial Safety Data
Ascletis Acne Phase 3 Clinical Trial Safety Data Denifanstat 50mg was Generally Well Tolerated During the 12-week Study Adverse events (AEs): AE incidence rates were comparable between denifanstat and placebo Only two categories of AEs had an incidence rate of 5% or more: Dry eye (investigator repor
Slide 16: Ascletis Acne Open Label Phase 3 Trial
Ascletis Acne Open Label Phase 3 Trial* Denifanstat generally well-tolerated in the open label clinical trial * Ascletis data on file. Safety and efficacy endpoints of 50 mg denifanstat oral, once daily for 52 weeks versus placebo for 12 weeks and 50mg denifanstat oral once daily for 40 weeks. Total
Slide 17: Sagimet's Upcoming Development Programs
Sagimet’s Upcoming Development Programs
Slide 18: Planned Phase 3 Clinical Trial for Denifanstat in Acne
Planned Phase 3 Clinical Trial for Denifanstat in Acne Moderate to severe acne Multi-center placebo controlled 2:1 randomization Double-blind Once daily oral dosing 800 patients in US Co-primary endpoints at week 12 % patients who achieve IGA success (defined as at least a 2-point reduction in IGA f
Slide 19: FASN Inhibitor TVB-3567 FIH Ongoing Phase 1 Clinical Trial
A double-blind, randomized, placebo-controlled clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of TVB-3567 in healthy participants with or without acne Includes sebum analysis as pharmacodynamic readout 1. SAD = Single a
Slide 20: Potential Clinical Development Program for TVB-3567 in Acne
Potential Clinical Development Program for TVB-3567 in Acne Step 1 - Phase 1 first-in-human pharmacokinetic (PK) clinical trial of TVB-3567 in healthy volunteers PK and pharmacodynamics (PD) evaluation to confirm profile Assess safety/tolerability Identify potential doses for an acne Phase 2 clinica
Slide 21: Denifanstat for Treatment of MASH
Denifanstat for Treatment of MASH Clinical and pre-clinical data demonstrate denifanstat’s potential to treat MASH (metabolic dysfunction-associated steatohepatitis) MASH F2-F3: Denifanstat met both primary endpoints in Phase 2b clinical trial, with significant reduction in fibrosis and was generall
Slide 22: FASN Inhibition – Significant Opportunity for a Novel Treatment for Acne
FASN Inhibition – Significant Opportunity for a Novel Treatment for Acne FASN Inhibition in Acne Potential of TVB-3567 in Acne Acne market is significant (~50m people in the US) and aligned to those patients most likely to be prescribed an oral FASN inhibitor Oral FASN inhibitors offer a novel mecha